Announced Fri, 31 Jul · 17:13 IST
Q1 FY27 results, Rs 50 Cr loan to subsidiary, MD re-appointment
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹374.50
prior close
₹375.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.7-2.1-2.0-2.9-2.9-4.5+1.2+0.4-0.1-5.5-0.1——
Up moveDown movePending
AI summary
Board approved Q1 FY27 (ended June 30, 2026) standalone and consolidated results. Standalone revenue rose 5.6 percent YoY to Rs 206.96 Cr; net profit jumped 16 percent to Rs 21.13 Cr (EPS Rs 2.26 vs Rs 2.05). Consolidated net profit at Rs 20.91 Cr. Board re-appointed CMD Mr. Ramesh Babu Potluri for 5 years from Oct 1, 2026. Approved Rs 50 Cr unsecured loan to subsidiary SMS Peptides, subject to shareholder approval. 38th AGM on Sep 23, 2026; record date Sep 16, 2026 for dividend eligibility.
Likely market impact
Revenue and profit growth YoY; Rs 50 Cr loan to subsidiary needs shareholder approval; dividend record date set.